Janux Therapeutics (NASDAQ:JANX) Stock Crosses Above 50 Day Moving Average – Here’s What Happened

Janux Therapeutics, Inc. (NASDAQ:JANX)’s stock price passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $17.49 and traded as high as $17.81. Janux Therapeutics shares last traded at $17.63, with a volume of 852,234 shares.

Key Stories Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

Wall Street Analyst Weigh In

JANX has been the topic of a number of research reports. Guggenheim decreased their price objective on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Truist Financial upped their target price on Janux Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday. HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a research note on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Friday, October 16th. Finally, Wedbush lifted their price target on shares of Janux Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Janux Therapeutics has an average rating of “Moderate Buy” and an average target price of $36.92.

Janux Therapeutics Stock Performance

The company has a fifty day moving average of $17.49 and a two-hundred day moving average of $15.42. The company has a market cap of $1.08 billion, a PE ratio of -11.09 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. The company had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $8.03 million. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.70 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Janux Therapeutics in the 2nd quarter valued at about $94,228,000. Bank of America Corp DE purchased a new position in Janux Therapeutics during the 2nd quarter valued at about $13,985,000. Nantahala Capital Management LLC purchased a new position in Janux Therapeutics during the 2nd quarter valued at about $12,440,279. Irenic Capital Management LP acquired a new position in Janux Therapeutics during the first quarter worth about $10,645,000. Finally, Algert Global LLC raised its position in Janux Therapeutics by 150.5% during the second quarter. Algert Global LLC now owns 1,110,889 shares of the company’s stock worth $17,063,000 after acquiring an additional 667,492 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.